Stem Cell Infusion: Clinical Trials

14 trials of Stem Cell Infusion, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 5 terminated, 1 withdrawn. 14 Phase 1, 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 114Completed 8, Terminated 5, Withdrawn 1
Phase 29Terminated 5, Completed 3, Withdrawn 1

Follow Stem Cell Infusion: new trials by email Literature Review of Stem Cell Infusion trials Research Report on Stem Cell Infusion

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Siplizumab for Sickle Cell Disease Transplant
Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell
Phase 1 / Phase 2TerminatedColumbia University12023-09-282026-06-10
URMC Related Haplo-identical Donor BMT
Total Body Irradiation 1200 cGy, Fludarabine, Pre-Stem Cell Infusion Cyclophosphamide - Hematological Disease, Immune Deficiencies
Phase 1CompletedUniversity of Rochester742015-10-012021-11-03
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Fludarabine, Melphalan, Alemtuzumab - Leukemia, Myeloma
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center32013-12-272019-07-16
Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin
Stem cell infusion - Critical Limb Ischemia (CLI)
Phase 1 / Phase 2TerminatedAndalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud202011-09-012018-12-19
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
Vorinostat, Gemcitabine, Busulfan - Lymphoma
Phase 1CompletedM.D. Anderson Cancer Center782011-08-012015-11-18
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias
Natural Killer (NK) Cell Infusion, Stem Cell Infusion - Leukemia, Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)342011-01-292019-08-22
Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant
G-CSF, AMD3100, Leukapheresis - Stem Cell Transplant Patients
Phase 1CompletedWashington University School of Medicine292010-04-292017-01-25
Lenalidomide and High-Dose Melphalan
Lenalidomide, Melphalan, Stem Cell Infusion - Myeloma, Stem Cell Transplantation
Phase 1 / Phase 2CompletedM.D. Anderson Cancer Center612010-03-012016-06-06
Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children
Cord Blood Infusion, Intravenous Sham - Cerebral Palsy
Phase 1 / Phase 2WithdrawnAugusta University2010-01-012022-10-07
Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders
Campath -1H, Fludarabine, Anti-CD45 - Severe Combined Immunodeficiency Disease, Severe Primary Immunodeficiency Disorder
Phase 1 / Phase 2TerminatedBaylor College of Medicine32007-10-012013-07-02
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Busulfan, Gemcitabine, Melphalan - Leukemia, Lymphoma
Phase 1CompletedM.D. Anderson Cancer Center1452006-12-012016-06-03
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
Y Zevalin, In Zevalin, Rituxan - Lymphoma
Phase 1 / Phase 2CompletedM.D. Anderson Cancer Center402003-09-012014-09-11
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
ANTI-CD45, CAMPATH-1H, FK506 - Hematologic Malignancy
Phase 1 / Phase 2CompletedBaylor College of Medicine242002-11-012012-06-29
Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia
CAMPATH-1H, Anti-CD45, Fludarabine - Fanconi Anemia, Severe Aplastic Anemia
Phase 1 / Phase 2TerminatedBaylor College of Medicine52001-07-012018-05-24

Conditions studied

Lymphoma (6)  ·  Hodgkin Disease (4)  ·  Multiple Myeloma (4)  ·  Leukemia (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Neoplasms, Plasma Cell (3)  ·  Anemia, Aplastic (2)  ·  Hematologic Neoplasms (2)  ·  Myelodysplastic Syndromes (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Anemia, Sickle Cell (1)  ·  Cerebral Palsy (1)  ·  Chronic Limb-Threatening Ischemia (1)  ·  Disease (1)  ·  Fanconi Anemia (1)

Sponsors

M.D. Anderson Cancer Center (5)  ·  Baylor College of Medicine (3)  ·  Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud (1)  ·  Augusta University (1)  ·  Columbia University (1)  ·  National Cancer Institute (NCI) (1)  ·  University of Rochester (1)  ·  Washington University School of Medicine (1)

Countries

United States (13)  ·  Spain (1)

Top investigators

Bernat Soria (1)  ·  Issa F. Khouri, MD,BS (1)  ·  James E Carroll, M.D. (1)  ·  Jeffrey Andolina, MD (1)  ·  John DiPersio, M.D., Ph.D. (1)  ·  Malcolm Brenner, M.B., Ph.D., (1)  ·  Malcolm Brenner, MD (1)  ·  Malcolm K Brenner, MD (1)  ·  Markus Y Mapara, MD, PhD (1)  ·  Muzaffar H. Qazilbash, MD (1)  ·  Nirali N Shah, M.D. (1)  ·  Richard E. Champlin, MD, BS (1)  ·  Robert Krance, MD (1)  ·  Yago Nieto, MD, PhD (1)  ·  Yago Nieto, MD,PHD (1)

Results publications

PMID 25452614, PMID 26071868, PMID 29476021, PMID 30826465, PMID 33951890